Troy Cox has served as a member of our Board since January 2024, after previously serving as a member of the board of directors of SomaLogic since September 2021 and as Executive Chair of SomaLogic from October 17, 2022 through March 28, 2023 and prior to that, on the board of directors of CM Life Sciences II. Mr. Cox has served as a director of SOPHiA GENETICS SA (Nasdaq: SOPH) since July 2019 and as its Chairperson since February 2020, as a member of the board of directors of LetsGetChecked Inc. since October 2019, Zymeworks Inc. (NYSE: ZYME) since June 2019, and Biosplice Therapeutics since April 2021. Mr. Cox also currently serves on the board of directors of Dream Foundation non-profit and previously of Massachusetts BioTechnology Council. Mr. Cox previously led Foundation Medicine, Inc. ( Foundation Medicine ) as President and Chief Executive Officer from February 2017 to February 2019, including through its acquisition by Roche in July 2018. Prior to Foundation Medicine, Troy served as Senior Vice President and an officer at Genentech, Inc. from February 2010 to February 2017. Prior to that, Mr. Cox held executive and senior roles of increasingly broad accountabilities including president at UCB BioPharmaceuticals, Senior Vice President at Sanofi-Aventis and diverse foundational roles at Schering-Plough. Mr. Cox received an M.B.A. from the University of Missouri and B.B.A. in Finance from the University of Kentucky. We believe that Mr. Cox s qualifications to serve on our Board include his extensive operational and strategic experience in the life sciences industry as an executive as well as a board director and in connection with evaluation and execution of business transaction and merger opportunities.